ArticleFrontiers in genetics2026
Developmental and epileptic encephalopathies with germline
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diseases associated with the germline Methods: We identified five germline missense pathogenic/likely pathogenic variants in Results: In all probands, the clinical symptoms included early-onset epilepsy, hypotonia, dysmorphic features, and variable congenital anomalies. A literature review of 107 cases supports reclassification of the phenotypic spectrum into severe (15.9%), intermediate (72.0%), and milder (12.1%) categories. Notably, the phenotypes of the five cases were classified as severe (n = 2) or milder (n = 3), consistent with prior reports, but revealed population-specific traits such as universal febrile sensitivity and normal serum alkaline phosphatase levels that are in contrast to elevated levels often noted in Western cohorts. The three children with the milder phenotype were found to have pathogenic/likely pathogenic variants located in exon 2, while the two severe phenotypes showed these variants located in exons 3 and 5. Conclusion: Overall, we report three novel pathogenic/likely pathogenic variants that expand clinicians' understanding of the genetic diversity within this phenotypic spectrum. These insights are expected to be valuable for future pathogenic/likely pathogenic variant analysis and accurate classification of clinical subtypes, which would help improve the understanding of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.